Literature DB >> 28987882

Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide.

Oliver K Appelbe1, Kelly D Moynihan2, Amy Flor1, Nick Rymut1, Darrell J Irvine3, Stephen J Kron4.   

Abstract

Along with vaccines and checkpoint blockade, immune adjuvants may have an important role in tumor immunotherapy. Oligodeoxynucleotides containing unmethylated cytidyl guanosyl dinucleotide motifs (CpG ODN) are TLR9 ligands with attractive immunostimulatory properties, but intratumoral administration has been required to induce an effective anti-tumor immune response. Following on recent studies with radiation-targeted delivery of nanoparticles, we examined enhanced tumor-specific delivery of amphiphile-CpG, an albumin-binding analog of CpG ODN, following systemic administration 3days after tumor irradiation. The combination of radiation and CpG displayed superior tumor control over either treatment alone. Intravital imaging of fluorescently labeled amphiphilic-CpG revealed increased accumulation in irradiated tumors along with decreased off-target accumulation in visceral organs. Within 48h after amphiphile-CpG administration, immune activation could be detected by increased Granzyme B and Interferon gamma activity in the tumor as well as in circulating monocytes and activated CD8+ T cells. Using radiotherapy to enhance the targeting of CpG to tumors may help advance this once promising therapy to clinical relevance.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer therapeutic efficacy; CpG oligodeoxynucleotides; Enhanced permeability and retention; Immune adjuvant; Ionizing radiation

Mesh:

Substances:

Year:  2017        PMID: 28987882      PMCID: PMC5723529          DOI: 10.1016/j.jconrel.2017.09.043

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  53 in total

Review 1.  Toll-like receptors in the induction of the innate immune response.

Authors:  A Aderem; R J Ulevitch
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

2.  Macrophages ingest and are activated by bacterial DNA.

Authors:  K J Stacey; M J Sweet; D A Hume
Journal:  J Immunol       Date:  1996-09-01       Impact factor: 5.422

3.  Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.

Authors:  Kathryn A Mason; Hisanori Ariga; Robert Neal; David Valdecanas; Nancy Hunter; Arthur M Krieg; John K Whisnant; Luka Milas
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

4.  Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.

Authors:  T R Jones; N Obaldia; R A Gramzinski; Y Charoenvit; N Kolodny; S Kitov; H L Davis; A M Krieg; S L Hoffman
Journal:  Vaccine       Date:  1999-08-06       Impact factor: 3.641

5.  CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans.

Authors:  H L Davis; I I Suparto; R R Weeratna; D D Iskandriati; S S Chamzah; A A Ma'ruf; C C Nente; D D Pawitri; A M Krieg; W Smits; D D Sajuthi
Journal:  Vaccine       Date:  2000-03-17       Impact factor: 3.641

6.  CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma.

Authors:  T L Warren; C E Dahle; G J Weiner
Journal:  Clin Lymphoma       Date:  2000-06

7.  Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis.

Authors:  T Sparwasser; L Hültner; E S Koch; A Luz; G B Lipford; H Wagner
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

8.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.

Authors:  Pilar Nava-Parada; Guido Forni; Keith L Knutson; Larry R Pease; Esteban Celis
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 9.  Albumin as a versatile platform for drug half-life extension.

Authors:  Darrell Sleep; Jason Cameron; Leslie R Evans
Journal:  Biochim Biophys Acta       Date:  2013-04-29

10.  Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.

Authors:  K Boggio; G Nicoletti; E Di Carlo; F Cavallo; L Landuzzi; C Melani; M Giovarelli; I Rossi; P Nanni; C De Giovanni; P Bouchard; S Wolf; A Modesti; P Musiani; P L Lollini; M P Colombo; G Forni
Journal:  J Exp Med       Date:  1998-08-03       Impact factor: 14.307

View more
  7 in total

1.  Self-Assembly as a Molecular Strategy to Improve Immunotherapy.

Authors:  Eugene Froimchuk; Sean T Carey; Camilla Edwards; Christopher M Jewell
Journal:  Acc Chem Res       Date:  2020-10-19       Impact factor: 22.384

2.  Environmentally Triggerable Retinoic Acid-Inducible Gene I Agonists Using Synthetic Polymer Overhangs.

Authors:  Christian R Palmer; Max E Jacobson; Olga Fedorova; Anna M Pyle; John T Wilson
Journal:  Bioconjug Chem       Date:  2018-01-19       Impact factor: 4.774

3.  PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.

Authors:  Yuan Zhuang; Sihan Li; Huihui Wang; Jingbo Pi; Yuhui Xing; Guang Li
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

Review 4.  Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics.

Authors:  Simon Van Herck; Bruno G De Geest
Journal:  Acta Pharmacol Sin       Date:  2020-05-25       Impact factor: 6.150

5.  Targeted Delivery of Immunostimulatory CpG Oligodeoxynucleotides to Antigen-Presenting Cells in Draining Lymph Nodes by Stearic Acid Modification and Nanostructurization.

Authors:  Makoto Nagaoka; Wenqing Liao; Kosuke Kusamori; Makiya Nishikawa
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

Review 6.  Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity.

Authors:  Zhangchi Dongye; Jian Li; Yuzhang Wu
Journal:  Br J Cancer       Date:  2022-07-28       Impact factor: 9.075

Review 7.  The promise and challenge of cancer microbiome research.

Authors:  Sumeed Syed Manzoor; Annemiek Doedens; Michael B Burns
Journal:  Genome Biol       Date:  2020-06-02       Impact factor: 13.583

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.